IBA and Tractebel announce partnership to support proton therapy construction projects
15 Mars 2022 - 3:00PM
IBA and Tractebel announce partnership to support proton therapy
construction projects
Louvain-la-Neuve, Belgium, March 15,
2022 IBA (Ion Beam Applications S.A., EURONEXT), the world
leader in particle accelerator technology, and Tractebel, a global
engineering company, announced today a partnership agreement to
support IBA’s customers with their proton therapy design and
construction projects.
As part of the agreement, IBA will promote
Tractebel’s consulting services to its prospective customers
relating to the design and construction of their proton therapy
facilities. Tractebel’s unique experience in providing engineering
services, consultancy and training in complex healthcare activities
will be a valuable extension to IBA’s customer offering, providing
customers with support in the construction process. Co-marketing
activities and extended services offerings will also be offered to
supply IBA’s customers with more detailed information on proton
therapy construction projects and Tractebel’s expertise.
The two companies have already collaborated on
several projects, such as structural integrity reviews in the event
of an earthquake, cost estimation tools for IBA’s Proteus
facilities, stability studies related to the installation of a
Proteus®ONE1 system into an existing Proteus®PLUS1 vault and
engineering support for the design of proton therapy facilities
including BIM (Building Information Modeling) model.
Luk Herremans, Executive Vice President
Commercial Operations Proton Therapy at IBA said: “We have
worked for several years with Tractebel on a variety of projects.
It has enabled Tractebel to gain an extensive knowledge of the
building requirements of our proton therapy systems, making them
the perfect design and engineering partner. Listening to the
market, there is an obvious need for a company that can guide our
customers through the design and building journey and help them to
make it as efficient and smooth as possible. We look forward to
collaborating with Tractebel to offer an even more complete service
to the market.”
Bernard Dereeper, Head of Business
Development & Strategy – Business Line Nuclear
at Tractebel added: “We are
honored to join forces once again with IBA, a global leader in
proton therapy and medical equipment. Combining our expertise in
designing medical installations, our nuclear- and radiation-related
competences and our multidisciplinary approach with IBA’s
world-class radiation therapy technology will enable us to offer
high-level and fully integrated services from facilities' design
and engineering to the system itself. We are proud that our
engineers’ know-how will contribute to improving cancer treatment
around the world.”
*** Ends ***About IBA
IBA (Ion Beam Applications S.A.) is the world
leader in particle accelerator technology. The company is the
leading supplier of equipment and services in the field of proton
therapy, considered to be the most advanced form of radiation
therapy available today. IBA is also a leading player in the fields
of industrial sterilization, radiopharmaceuticals and dosimetry.
The company, based in Louvain-la-Neuve, Belgium, employs
approximately 1,500 people worldwide. IBA is a certified B
Corporation (B Corp) meeting the highest standards of verified
social and environmental performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
About TractebelTractebel is a
global engineering company delivering game-changing solutions for a
carbon-neutral future. Insights gathered during our more than 150
years of experience in energy, urban, nuclear and water projects
combined with local expertise allow us to tackle complex
future-oriented projects. By connecting strategy, design,
engineering and project management, our community of 5,000
imaginative experts helps companies and public authorities create
positive impact towards a sustainable world, where people, planet
and profit collectively thrive. Tractebel is part of the ENGIE
Group, a global reference in low-carbon energy and services, and
has offices in Europe, Africa, Asia, the Middle East and Latin
America. In the healthcare sector, Tractebel provides full scope
engineering and consultancy services from design, construction and
operation support to decommissioning of radiotherapy and nuclear
medicine facilities.
More information can be found at:
https://tractebel-engie.com/en
For further information, please
contact:
IBAOlivier LechienCorporate
Communication Director+32 10 475
890communication@iba-group.com For media and
investor enquiries: Consilium Strategic Communications
Amber Fennell, Angela Gray, Lucy Featherstone +44 (0) 20 3709 5700
IBA@consilium-comms.com |
TractebelBernard
DereeperHead of Business Development &
Strategy – Business Line Nuclear +32 485 46 82
25nuc-news@tractebel.engie.com For media
enquiries:Daphné
CharletonCommunication Manager
Nuclear+32 498 72 28
41daphne.charleton@tractebel.engie.com |
1 Proteus®ONE and Proteus®PLUS are brand names of Proteus
235
- 20220315-IBA-Tractebel-cooperation-agreement-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024